financetom
Business
financetom
/
Business
/
Plasma-based technology provider PyroGenesis' Q3 revenue declines, gross margin falls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Plasma-based technology provider PyroGenesis' Q3 revenue declines, gross margin falls
Nov 12, 2025 1:28 AM

Overview

* PyroGenesis ( PYRGF ) Q3 revenue falls 18.7% yr/yr, reflecting project phase fluctuations

* Gross margin declines to 24% from 42% in Q3 2024

* Company secures C$1.2 mln contract with cement industry customer

Outlook

* Company is not providing specific revenue or net income guidance for 2025

* Company focuses on innovation in high temperature processes for heavy industry

* Company sees significant market opportunity in heavy industries and defense

Result Drivers

* NEW CONTRACTS - Secured a C$1.2 mln contract with a cement industry customer for plasma torch system, highlighting expansion into new sectors

* FUMED SILICA ADVANCES - Significant progress in fumed silica reactor, tripling material surface area performance, moving closer to commercial readiness

* STRATEGIC VERTICALS - New agreements in Europe for plastic waste and energy transition projects with Constellium show strength in strategic verticals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 C$3.25

Revenue mln

Q3 Gross 24.00%

Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved